Nature communications · 2022
A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin.
СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qiu Deyun, Pei Jinxin V, Rosling James E O, Thathy Vandana, Li Dongdi, Xue Yi, Tanner John D, Penington Jocelyn Sietsma, Aw Yi Tong Vincent, Aw Jessica Yi Han, Xu Guoyue, Tripathi Abhai K, Gnadig Nina F, Yeo Tomas, Fairhurst Kate J, Stokes Barbara H, Murithi James M, Kümpornsin Krittikorn, Hasemer Heath, Dennis Adelaide S M, Ridgway Melanie C, Schmitt Esther K, Straimer Judith, Papenfuss Anthony T, Lee Marcus C S, Corry Ben, Sinnis Photini, Fidock David A, van Dooren Giel G, Kirk Kiaran, Lehane Adele M
Аннотация
Diverse compounds target the Plasmodium falciparum Na+ pump PfATP4, with cipargamin and (+)-SJ733 the most clinically-advanced. In a recent clinical trial for cipargamin, recrudescent parasites emerged, with most having a G358S mutation in PfATP4. Here, we show that PfATP4G358S parasites can withstand micromolar concentrations of cipargamin and (+)-SJ733, while remaining susceptible to antimalarials that do not target PfATP4. The G358S mutation in PfATP4, and the equivalent mutation in Toxoplasma gondii ATP4, decrease the sensitivity of ATP4 to inhibition by cipargamin and (+)-SJ733, thereby protecting parasites from disruption of Na+ regulation. The G358S mutation reduces the affinity of PfATP4 for Na+ and is associated with an increase in the parasite's resting cytosolic [Na+]. However, no defect in parasite growth or transmissibility is observed. Our findings suggest that PfATP4 inhibitors in clinical development should be tested against PfATP4G358S parasites, and that their combination with unrelated antimalarials may mitigate against resistance development.